Spruce Biosciences (NasdaqCM:SPRB) 2026 Conference Transcript

Summary of Spruce Biosciences Conference Call Company Overview - Company: Spruce Biosciences (NasdaqCM:SPRB) - Focus: Development of therapies for rare diseases, specifically targeting MPS IIIB (NAGLU deficiency) Key Points Regulatory Interactions - Received Breakthrough Therapy designation from the FDA in October 2025, facilitating two meetings to discuss CMC and clinical matters [11][12] - FDA has been positive in discussions, acknowledging the severity of the disease and the lack of alternatives for patients [11] - The company plans to submit its BLA (Biologics License Application) in the fourth quarter of 2026, delaying to include the first PPQ (Process Performance Qualification) batch from validation runs [15][38] Clinical Data and Biomarkers - The FDA has validated the use of heparan sulfate non-reducing ends as a surrogate endpoint for accelerated approval, showing a strong correlation with clinical benefit [16][17] - Clinical data indicates nearly 100% correlation between heparan sulfate levels and non-reducing ends, supporting the use of these biomarkers [16] - The company has demonstrated a favorable effect on clinical endpoints, including Bayley raw scores and Vineland scores, which measure adaptive behavior [23][24] Confirmatory Trial Design - The confirmatory trial design has been discussed with the FDA, focusing on patient rescue protocols and ensuring timely treatment effects [32][33] - Enrollment is projected to take about 18 months, with no interim analyses planned [33] Commercial Strategy - A new Chief Commercial Officer, Dale Hooks, has been appointed to lead the commercial strategy for MPS IIIB [44] - The strategy includes identifying patients, building a medical affairs plan, and addressing pricing and market access [45][46] - The company estimates around 160 prevalent cases of MPS IIIB, with potential for higher numbers based on broader epidemiological data [51][59] Financial Outlook - As of the end of 2025, the company has approximately $50 million in cash, expected to sustain operations into 2027 [62] - The company has access to a debt facility linked to regulatory milestones, which may help bridge any cash shortfalls before the PDUFA date [64] Market Potential - The company anticipates a peak patient population of around 500 patients in the U.S. and globally, based on improved patient longevity and incidence rates [61] Additional Insights - The FDA's feedback on the confirmatory trial and the use of heparan sulfate as a biomarker is seen as a significant advantage compared to competitors [27][28] - The company is monitoring developments in newborn screening policies that could impact early diagnosis and treatment access [50] This summary encapsulates the critical insights from the conference call, highlighting the company's regulatory progress, clinical data, commercial strategy, and financial outlook.